Table: Anges - 6-MTH group results
Jul 30 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Jun 30, 2020 Jun 30, 2019 Dec 31, 2020
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 16 mln 172 mln
(-90.2 pct) (-1.9 pct)
Operating loss 1.77 loss 1.71
Recurring loss 1.90 loss 1.73
Net loss 1.90 loss 1.97
EPS loss 16.58 yen loss 19.26 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001